Supplies products for medical communities. Offers products for dental communities. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
An investor who bought at the very peak is down 90% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Our checks did not surface a specific strength to highlight here.
A loss of $30K against $0 in annual sales.
The stock sits at $0.02. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
The stock trades 90% below its five-year peak.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
The takeaway: TRDX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.